Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 9/20 | 0.54 |
| ▸ | IDO1 | P14902 | 8/20 | 0.54 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458344 | 0.81 | TDO2 (0.60) | TDO2IDO1METTL3CYP2C9 | |
| SCHEMBL459193 | 0.81 | TDO2 (0.53) | TDO2IDO1METTL3FBP1 | |
| SCHEMBL31158048 | 0.81 | TDO2 (0.53) | TDO2IDO1METTL3FBP1 | |
| SCHEMBL16806087 | 0.79 | IDO1 (0.53) | TDO2IDO1METTL3METAP2DHODH | |
| SCHEMBL2595232 | 0.79 | METAP2 (0.51) | METAP2 | |
| SCHEMBL23115879 | 0.77 | ALDH1A1 (0.51) | TDO2IDO1METTL3 | |
| SCHEMBL16804164 | 0.76 | DHPS (0.42) | TDO2IDO1METAP2PTPN6 | |
| SCHEMBL5446859 | 0.76 | METAP2 (0.55) | TDO2IDO1METAP2PTPN6 | |
| SCHEMBL23809264 | 0.76 | METAP2 (0.55) | TDO2IDO1METAP2DHODH | |
| SCHEMBL27871147 | 0.76 | IDO1 (0.50) | TDO2IDO1FBP1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431234-A | Benzyl amine formyl compound and preparation method and application thereof | 中国药科大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-114805350-B | Benzo heterocycle-pyridone derivative, and preparation method and application thereof | 四川大学华西医院 | 2023-10-20 | — | — | CN | disclosed |
| CN-114805350-A | Benzo-heterocycle-pyridone derivatives and preparation method and application thereof | 四川大学华西医院 | 2022-07-29 | — | — | CN | disclosed |
| CN-106456602-A | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2017-02-22 | — | — | CN | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| CN-105555766-A | Aminomethyl-biaryl derivatives as complement factor D inhibitors and uses thereof | NOVARTIS AG | 2016-05-04 | — | — | CN | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2406255-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | Glaxo Group Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | TDO2 2952/4885IDO1 113/4885METTL3 626/4885 |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | CDK3, CDK13, AKT3 | TDO2 3188/4885IDO1 1459/4885METTL3 3069/4885 |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | TDO2 3198/4885IDO1 1024/4885METTL3 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.